FindTrial
Sign In

Comparative study for 18F-FDG and 68Ga-PSMA PET/CT examination in patients with suspected or castration-resistant prostate cancer and its clinical significance

Comparative study for 18F-FDG and 68Ga-PSMA PET/CT examination in patients with suspected or castration-resistant prostate cancer and its clinical significance

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800020406
Enrollment
Unknown
Registered
2018-12-28
Start date
2019-01-01
Completion date
Unknown
Last updated
2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

Gold Standard:Pathological biopsy results PSA levels after clinical treatment
Index test:SUV,&#32
PSA&#32
level,&#32
pathology,&#32
Immunohistochemistry,&#32
MRI,&#32
PET/CT,&#32
SPECT/CT,&#32
Gleason&#32
scores

Sponsors

First Affiliated Hospital of Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Adult male; 2. Suspicious increase in PSA; 3. Other patients with suspected prostate cancer suspected; 4. Patients with castration resistant prostate cancer; 5. Re-examination after treatment; 6. Signed an informed consent form and accept 18F-FDG and 68Ga-PSMA PET/CT examination.

Exclusion criteria

Exclusion criteria: 1. The patient's physical condition cannot be tolerated; 2. There are birth plans in the recent 6 months; 3. Serious liver and kidney diseases, etc.

Design outcomes

Primary

MeasureTime frame
SUV;PSA;pathology;—

Countries

China

Contacts

Public ContactXinlu Wang

First Affiliated Hospital of Guangzhou Medical University

71lu@163.com+86 13226616001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026